Mesoblast (MESO) Income from Continuing Operations (2015 - 2023)
Mesoblast's (MESO) quarterly Income from Continuing Operations came in at 21959000.0 in Q2 2023, down 0.57% year-on-year from 22084416.42 in Q2 2022, and down 17.77% quarter-over-quarter from 18646000.0 in Q1 2023.
Mesoblast (MESO) Income from Continuing Operations (2015 - 2023) Analysis & Trends
Mesoblast has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 21959000.0 for Q2 2023.
- Income from Continuing Operations for Q2 2023 came in at 21959000.0, down 0.57% year-over-year; the trailing twelve-month figure through Jun 2023 was 82172000.0 (up 10.69% YoY), and the FY2025 annual result was 102142000.0, down 16.13% from the prior year.
- Income from Continuing Operations came in at 21959000.0 for Q2 2023 at Mesoblast, down from 18646000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7416000.0 in Q3 2019 to a low of 29380000.0 in Q1 2019.
- The 5-year median for Income from Continuing Operations is 22364000.0 (2021), against an average of 22525055.56.
- Across the five-year window, Income from Continuing Operations soared 64.55% in 2019 and slumped 250.65% in 2020, its largest moves.
- Mesoblast's Income from Continuing Operations stood at 29122000.0 in 2019, then increased by 12.29% to 25544000.0 in 2020, then declined by 2.2% to 26105000.0 in 2021, then advanced by 5.66% to 24628000.0 in 2022, then climbed by 10.84% to 21959000.0 in 2023.
- The last three Income from Continuing Operations figures came in at 21959000.0 (Q2 2023), 18646000.0 (Q1 2023), and 24628000.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.96 Mn |
| Mar 31, 2023 | -18.65 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -21.84 Mn |
| Mar 31, 2022 | -21.29 Mn |
| Dec 31, 2021 | -26.11 Mn |
| Sep 30, 2021 | -22.77 Mn |
| Jun 30, 2021 | -20.55 Mn |
| Mar 31, 2021 | -26.71 Mn |
| Dec 31, 2020 | -25.54 Mn |
| Sep 30, 2020 | -26.00 Mn |
| Jun 30, 2020 | -20.29 Mn |
| Mar 31, 2020 | -19.17 Mn |
| Dec 31, 2019 | -29.12 Mn |
| Sep 30, 2019 | -7.42 Mn |
| Jun 30, 2019 | -27.08 Mn |
| Mar 31, 2019 | -29.38 Mn |
| Dec 31, 2018 | -30.33 Mn |
| Sep 30, 2018 | -20.92 Mn |